# Medication-Overuse Headache

Medication-overuse headache requires recognition of class-specific acute-medication thresholds, exclusion of alternative secondary headache causes, and a planned withdrawal strategy. Most patients stop nonopioid acute agents abruptly while migraine prevention and close follow-up address withdrawal symptoms, persistent migraine, and relapse risk.

**Clinical question:** How should clinicians identify and treat medication-overuse headache while managing withdrawal and the underlying primary headache disorder?

Updated: 2026-08-24T16:34:07.347206+00:00

## What matters in practice
- Diagnose medication-overuse headache when headache occurs on more than 15 days per month with overuse for more than 3 months: at least 10 days monthly for triptans, opioids, ergots, or combination analgesics, or at least 15 days monthly for simple analgesics or NSAIDs. [20][22]
- Withdrawal of the overused acute medication is the central intervention; abrupt cessation is generally preferred for analgesics and triptans, whereas opioids should be tapered and warrant assessment for dependence-related complications. [2][22]
- Start or optimize preventive therapy for the antecedent headache disorder during withdrawal or after its re-emergence; for chronic migraine, supported preventive options include topiramate, onabotulinumtoxinA, and CGRP monoclonal antibodies. [2]
- Warn patients that headache commonly worsens before recovery after stopping acute medication, then reassess attack frequency, severity, disability, and acute-medication days within 2 to 3 months. [2][13]

## Confirm the medication-use pattern before attributing chronic headache to overuse

A medication diary is the highest-yield first test.

Obtain a prospective 30-day headache and medication diary that records headache days, acute-medication days by class, dose, and use of combination products. Diagnose medication-overuse headache when headache is present on more than 15 days per month, acute headache medication has been overused for more than 3 months, and headache developed or worsened during that exposure pattern. Patients with both chronic migraine and medication-overuse headache should retain both diagnoses because withdrawal does not replace treatment of the underlying migraine disorder. [19][22]

Classify overuse by medication days rather than total pills. The operational threshold is at least 10 days per month for triptans, ergotamine, opioids, and combination analgesics; combination products include agents such as Excedrin, barbiturate-containing products, and Midrin. The threshold is at least 15 days per month for aspirin, acetaminophen, ibuprofen, naproxen sodium, or other prescription NSAIDs used alone. Apply the multiple-class overuse category when aggregate acute-medication exposure meets overuse criteria although no single class does. [20][22]

Do not diagnose medication-overuse headache solely because the patient has frequent medication exposure. The association between acute-medication use and frequent headache is complicated by confounding from the underlying headache burden; use the diary together with temporal worsening during overuse and response after withdrawal to reassess the diagnosis. [21]
- Ask specifically about OTC acetaminophen, aspirin, ibuprofen, naproxen, caffeine-containing combination products, barbiturate-containing products, opioids, triptans, and ergotamine; patients may not identify OTC combination products as headache medication. [20]
- Document the antecedent headache phenotype and current headache-day burden before withdrawal so that residual migraine or another primary headache disorder can be treated after detoxification. [2][19]

*Medication-day thresholds used to identify acute medication overuse. [20][22]*

| Acute medication class | Overuse threshold | Clinical implication |
| --- | --- | --- |
| Triptans, ergotamine, opioids | At least 10 days per month for more than 3 months [20][22] | Meets class-specific overuse threshold in a patient with headache on more than 15 days monthly. [22] |
| Combination analgesics, including caffeine- or barbiturate-containing products | At least 10 days per month for more than 3 months [20][22] | Assign combination-analgesic-overuse headache when diagnostic criteria are met. [9] |
| Acetaminophen, aspirin, NSAIDs used alone | At least 15 days per month for more than 3 months [20][22] | Meets simple-analgesic overuse threshold in a patient with headache on more than 15 days monthly. [22] |
| Multiple acute-medication classes | Aggregate use may meet criteria when no single class reaches its individual threshold. [20] | Identify all contributing agents before constructing the withdrawal plan. [20] |

## Separate likely medication overuse from urgent secondary headache

Medication overuse should not terminate the secondary-headache assessment.

At the initial visit, compare the current headache with the patient's established phenotype and determine whether the frequency increase tracks acute-medication escalation. A stable migraine-like phenotype with qualifying medication exposure supports medication-overuse headache; a distinctly new phenotype, progressive focal neurologic symptoms, altered consciousness, systemic illness, or abrupt severe onset requires evaluation for an alternative secondary cause before assuming medication overuse.

Prioritize opioid exposure as a separate management branch. Opioids can contribute to medication-overuse headache and opioid-induced hyperalgesia, and abrupt discontinuation is not the default strategy for opioid overuse. Establish the prescribed and nonprescribed opioid regimen, duration of use, prior withdrawal symptoms, and concurrent sedative exposure, then select a tapering plan rather than an unsupervised abrupt stop. [4][2][22]

Refer chronic migraine with medication overuse to headache-specialist care when withdrawal fails, diagnostic uncertainty persists, opioid or other addictive-drug use complicates management, or preventive treatment selection requires escalation. Chronic migraine itself is a specialist-referral indication in the ten-step migraine management framework. [2]
- Use the diary to identify whether morning or persistent daily headache coincides with medication escalation; medication-overuse headache is often persistent and may be worst on awakening. [22]
- Reassess the diagnosis after withdrawal if headache frequency does not improve or the post-withdrawal phenotype is discordant with the presumed underlying disorder. [2][21]

*Management branches determined by the overused medication class. [2][4][22]*

| Clinical branch | Key discriminator | Next action |
| --- | --- | --- |
| Simple analgesic, NSAID, triptan, or combination-analgesic overuse | Qualifying medication-day threshold without opioid dependence concerns [20][22] | Explain expected transient worsening and plan abrupt withdrawal. [2][22] |
| Opioid overuse | Current opioid exposure, possible dependence, or concern for opioid-induced hyperalgesia [4] | Plan gradual taper rather than routine abrupt withdrawal; involve appropriate addiction or pain-management support when needed. [2][22] |
| Persistent chronic migraine after overuse is addressed | Headache remains frequent after medication withdrawal and reassessment [2] | Initiate or optimize migraine prevention with an evidence-based chronic migraine option. [2] |
| Atypical or changing headache syndrome | Current symptoms differ materially from the prior primary-headache phenotype | Evaluate for another secondary headache disorder before attributing the presentation to medication overuse. |

## Use an explicit withdrawal plan rather than a vague reduction target

Education and a defined stop date improve implementation.

Explain that medication withdrawal is the necessary core treatment and that headache usually worsens before recovery. For overused analgesics and triptans, use abrupt discontinuation rather than gradual dose reduction. This can usually be managed in primary care when addictive drugs are not involved; opioid exposure is the major exception and should be tapered. [2][22]

Set the withdrawal plan in writing: identify every acute agent to stop, establish the cessation date, review anticipated headache worsening and associated symptoms, and specify how the patient will contact the practice if withdrawal becomes unmanageable. Detoxification commonly produces predictable withdrawal symptoms, and successful detoxification is associated with improved headache outcomes and fewer monthly headache days by 8 weeks. [13]

Avoid allowing a bridge plan to become replacement overuse. Bridging therapies have been used to reduce withdrawal-headache intensity and associated symptoms, but novel acute agents including ditans and gepants require further study in this setting. If prednisone is selected for withdrawal symptoms, one cited primary-care guide lists prednisone 60 mg as possibly effective; the same guide lists amitriptyline up to 50 mg as possibly effective for withdrawal symptoms. [13][22]
- For analgesic or triptan overuse: stop the overused agent abruptly and prepare the patient for short-term worsening. [2][22]
- For opioid overuse: taper rather than abruptly discontinue; assess for opioid-related hyperalgesia and withdrawal risk. [4][2][22]
- Schedule active follow-up rather than waiting for the next routine visit, because early withdrawal symptoms can undermine adherence. [13]

### Preventive therapy during withdrawal

Preventive treatment for the antecedent migraine disorder can begin in parallel with acute-medication withdrawal or be initiated when the underlying headache disorder re-emerges; this timing remains debated. For chronic migraine once medication overuse has been addressed or excluded, evidence-based preventive options include topiramate, onabotulinumtoxinA, and CGRP monoclonal antibodies. [2]

When topiramate is chosen in medication-overuse headache, a cited primary-care guide identifies a maximum daily dose of 200 mg. Select the preventive agent according to the underlying migraine phenotype, prior response, comorbidities, adverse-effect risk, access, and patient preference rather than using detoxification as the sole treatment. [22][2]

*Practical withdrawal sequence for medication-overuse headache. [2][13][22]*

| Time point | Required action | Decision checkpoint |
| --- | --- | --- |
| Before withdrawal | Quantify medication days by class and identify the underlying headache disorder with a diary. [20][22] | Determine whether opioid exposure requires tapering rather than abrupt cessation. [2][22] |
| Withdrawal start | Abruptly stop overused analgesics or triptans; start a tapering strategy for opioids. [2][22] | Counsel that headache may worsen before recovery. [2][13] |
| During withdrawal | Start or optimize preventive treatment for the antecedent headache disorder when clinically appropriate. [2] | Do not substitute a new frequently used acute agent without tracking medication days. |
| About 8 weeks | Review headache days and acute-medication days after detoxification. [13] | If headache remains frequent, reassess diagnosis and optimize preventive therapy. [2] |

## Measure response by headache burden and medication days

Withdrawal success does not eliminate the need for migraine management.

At follow-up, review the same diary fields used at baseline: monthly headache days, monthly acute-medication days by class, attack severity, and migraine-related disability. Evaluate response shortly after initiating or changing therapy, at 2 to 3 months, then every 6 to 12 months once the regimen is stable. [2]

If outcomes remain suboptimal, first review whether medication overuse has recurred, whether the post-withdrawal phenotype still supports migraine, and whether the preventive strategy is being used and tolerated. A patient whose medication use no longer meets overuse thresholds but who continues to have frequent migraine needs escalation of migraine prevention rather than repeated detoxification alone. [2][20]

Prevent recurrence by discussing class-specific medication-day limits before prescribing or refilling acute treatment. Frequent acute-medication use is a modifiable risk factor for headache-frequency progression, and patients with migraine should be educated about medication-overuse risk before use becomes established. [2][21]
- At 2 to 3 months: compare attack frequency, severity, disability, and acute-medication days with baseline. [2]
- Every 6 to 12 months after stabilization: reassess efficacy, adverse effects, adherence, and return of overuse. [2]
- At every acute-medication refill: reconcile OTC and prescription headache agents against the 10-day and 15-day monthly thresholds. [20][22]

*Follow-up metrics that determine the next management step. [2][20][22]*

| Metric | Interpretation | Next step |
| --- | --- | --- |
| Acute-medication days by class | At least 10 days monthly for triptans, opioids, ergots, or combination analgesics, or at least 15 days monthly for simple analgesics, suggests recurrent overuse. [20][22] | Reinstitute a medication-withdrawal plan and reassess the preventive regimen. [2] |
| Headache frequency after withdrawal | Persistent frequent headaches may reflect inadequately treated chronic migraine or an alternative diagnosis. [2][21] | Reassess phenotype and optimize chronic migraine prevention. [2] |
| Attack severity and disability | Persistent burden despite reduced acute-medication use indicates incomplete control of the underlying headache disorder. [2] | Adjust preventive treatment and assess adherence and tolerability. [2] |
| Opioid use | Continued opioid exposure may sustain medication-overuse headache or opioid-induced hyperalgesia. [4] | Continue an individualized tapering and multidisciplinary management plan. [2][22] |

## References
1. Comparison of 3 Treatment Strategies for Medication ... — jamanetwork.com — https://jamanetwork.com/journals/jamaneurology/fullarticle/2766518
2. Diagnosis and management of migraine in ten steps — www.nature.com — https://www.nature.com/articles/s41582-021-00509-5
3. Migraine | Nature Reviews Disease Primers — www.nature.com — https://www.nature.com/articles/s41572-021-00328-4
4. PACAP-PAC1 receptor inhibition is effective in opioid ... — www.cell.com — https://www.cell.com/iscience/fulltext/S2589-0042(23)00027-5
5. The Many Faces of Medication‐Overuse Headache in Clinical ... — headachejournal.onlinelibrary.wiley.com — https://headachejournal.onlinelibrary.wiley.com/doi/10.1111/head.13785
6. Treatment of medication overuse headache – guideline ... — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/10.1111/j.1468-1331.2011.03497.x
7. American Headache Society 66th Annual Scientific Meeting ... — headachejournal.onlinelibrary.wiley.com — https://headachejournal.onlinelibrary.wiley.com/doi/10.1111/head.14771
8. overuse headache — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/ene.14268
9. European Academy of Neurology guideline on the ... — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/10.1111/ene.14268
10. Evidence Regarding Medication Overuse Headache in ... — headachejournal.onlinelibrary.wiley.com — https://headachejournal.onlinelibrary.wiley.com/doi/10.1111/head.13726
11. American Headache Society 67th Annual Scientific Meeting ... — headachejournal.onlinelibrary.wiley.com — https://headachejournal.onlinelibrary.wiley.com/doi/10.1111/head.14957
12. Medication Overuse - an overview — www.sciencedirect.com — https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/medication-overuse
13. Medication-overuse headache: Bridging therapies for detoxification — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S0303846725004883
14. Cluster Headache - an overview — www.sciencedirect.com — https://www.sciencedirect.com/topics/medicine-and-dentistry/cluster-headache
15. Drug Detoxification - an overview — www.sciencedirect.com — https://www.sciencedirect.com/topics/immunology-and-microbiology/drug-detoxification
16. SPINEPASS Randomized Clinical Trial Protocol | Physical ... — academic.oup.com — https://academic.oup.com/ptj/article/106/1/pzaf143/8362131
17. Primary Care Management of Headache - Oxford Academic — academic.oup.com — https://academic.oup.com/milmed/article/187/9-10/e1091/6504461
18. Pilot Study of Amitriptyline in the Prophylactic Treatment of ... — academic.oup.com — https://academic.oup.com/painmedicine/article-pdf/15/10/1803/11009524/15-10-1803.pdf
19. Eptinezumab With Patient Education for Chronic Migraine and Medication-Overuse Headache — www.neurology.org — https://www.neurology.org/doi/10.1212/WNL.0000000000214863
20. Medication Overuse and Headache Burden — www.neurology.org — https://www.neurology.org/doi/10.1212/CPJ.0000000000001037
21. Medication overuse headache — www.neurology.org — https://www.neurology.org/doi/10.1212/WNL.0000000000004371
22. PHC ENG GUIDE 200 - Extranet Systems — extranet.who.int — https://extranet.who.int/ncdccs/Data/LBN_D1_Final%20EN%20PHC%20Guide%20(September%2025,%202015).pdf
23. Why Should We Prescribe Medications to Treat Alcohol ... — www.aasld.org — https://www.aasld.org/liver-fellow-network/core-series/why-series/why-should-we-prescribe-medications-treat-alcohol-use
24. Electronic Signature Page — cdn.clinicaltrials.gov — https://cdn.clinicaltrials.gov/large-docs/39/NCT05452239/Prot_000.pdf

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.